Ascidian Therapeutics, Inc
Clinical trials sponsored by Ascidian Therapeutics, Inc, explained in plain language.
-
Gene therapy injection aims to slow vision loss in stargardt disease
Disease control Recruiting nowThis early study tests a single injection of ACDN-01 into the eye for people with Stargardt disease or related vision loss caused by ABCA4 gene mutations. The main goal is to check safety and find the best dose. Up to 15 adults with advanced vision loss will take part. The therap…
Phase: PHASE1, PHASE2 • Sponsor: Ascidian Therapeutics, Inc • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Eye disease prescreening opens door to future gene therapy trials
Knowledge-focused Recruiting nowThis study is a prescreening step to find people with a specific genetic eye condition called ABCA4-related retinopathy, which includes Stargardt disease and cone-rod dystrophy. About 50 participants will undergo genetic testing and eye exams to see if they qualify for future tri…
Sponsor: Ascidian Therapeutics, Inc • Aim: Knowledge-focused
Last updated May 26, 2026 07:41 UTC